2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1747

Predictors of Survival on Anti-TNF in an Observational Cohort of Patients with Ankylosing Spondylitis: The Role of MRI Parameters of Inflammation and Structural Damage
Abstract Number: 1745

Predictors of Sustained Remission on Anti-TNF in an Observational Cohort of Patients with Ankylosing Spondylitis: The Role of MRI Parameters of Inflammation and Structural Damage
Abstract Number: 2847

Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study
Abstract Number: 739

Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Abstract Number: 2521

Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes
Abstract Number: 2519

Pregnancy in Psoriatic Arthritis: A Case Series
Abstract Number: 2435

Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Abstract Number: 2624

Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis
Abstract Number: 2943

Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program
Abstract Number: 11L

Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
Abstract Number: 3173

Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Abstract Number: 2118

Prescription Medication Use in Community-Based US Adults with Chronic Low Back Pain: Nhanes 2009-2010
Abstract Number: 2537

Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Abstract Number: 1206

Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands
Abstract Number: 1376

Presence of the Interferon Signature in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].